Published in Drug Discov Today on September 11, 2012
The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One (2014) 1.16
DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep (2012) 1.02
Serum metabolomics of slow vs. rapid motor progression Parkinson's disease: a pilot study. PLoS One (2013) 0.95
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model. Mol Neurobiol (2013) 0.80
Mini Review: linkages between essential tremor and Parkinson's disease? Front Cell Neurosci (2013) 0.78
Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls. Front Aging Neurosci (2014) 0.78
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet (2008) 5.04
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology (2007) 3.62
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology (1996) 3.48
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol (2010) 3.15
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology (2009) 3.04
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Network modulation in the treatment of Parkinson's disease. Brain (2006) 2.52
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab (2006) 2.42
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry (1998) 2.24
Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab (2006) 2.16
Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain (2008) 2.10
Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord (2000) 2.10
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.98
The metabolic topography of parkinsonism. J Cereb Blood Flow Metab (1994) 1.89
Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology (2008) 1.86
Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing (1999) 1.83
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry (2007) 1.69
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
(18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol (2010) 1.61
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol (2010) 1.56
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol (2002) 1.54
Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology (2005) 1.54
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain (2011) 1.53
Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1992) 1.50
Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci (2010) 1.50
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun (2006) 1.45
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol (1997) 1.45
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage (2005) 1.40
Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry (1995) 1.39
Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain (2000) 1.35
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol (2001) 1.27
Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One (2009) 1.19
Imaging biomarkers in Parkinson's disease. Prog Neurobiol (2011) 1.19
(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol (2004) 1.19
Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord (2005) 1.19
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology (2008) 1.18
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol (2011) 1.15
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett (2007) 1.05
Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm (Vienna) (2004) 1.05
In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med (2010) 1.03
Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci (2009) 1.03
Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain (1997) 1.03
Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry (2009) 0.99
Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology (1993) 0.99
PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord (1993) 0.97
Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun (2006) 0.95
Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain (2005) 0.94
Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. Mov Disord (2010) 0.92
18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol (2007) 0.92
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm (Vienna) (2010) 0.92
Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord (2010) 0.92
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand (2010) 0.91
Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull (2006) 0.90
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. Neurology (2011) 0.87
Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients. Chin Med J (Engl) (2012) 0.85
Amyloid-β and τ biomarkers in Parkinson's disease-dementia. J Neurol Sci (2011) 0.85
Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin Chim Acta (2008) 0.83
Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse (1998) 0.82
Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease. Neurosci Lett (2010) 0.80
[Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease]. Mol Biol (Mosk) (2011) 0.76
Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease? Exp Neurol (2011) 0.75
Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 6.55
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol (2013) 4.03
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J (2010) 3.90
Antagonistic regulation of PIN phosphorylation by PP2A and PINOID directs auxin flux. Cell (2007) 3.84
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mice genetically deficient in vasopressin V1a and V1b receptors are resistant to jet lag. Science (2013) 3.51
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res (2010) 2.87
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
MicroRNA identification based on sequence and structure alignment. Bioinformatics (2005) 2.52
ABP1 mediates auxin inhibition of clathrin-dependent endocytosis in Arabidopsis. Cell (2010) 2.51
Approaches for high internal quantum efficiency green InGaN light-emitting diodes with large overlap quantum wells. Opt Express (2011) 2.44
Subcellular homeostasis of phytohormone auxin is mediated by the ER-localized PIN5 transporter. Nature (2009) 2.40
In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Res (2007) 2.28
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Automatic detection and recognition of signs from natural scenes. IEEE Trans Image Process (2004) 2.19
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood (2005) 2.17
Sperm, but not oocyte, DNA methylome is inherited by zebrafish early embryos. Cell (2013) 2.16
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat Med (2012) 2.13
A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab Chip (2007) 2.03
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Altered heart rate variability depend on the characteristics of coronary lesions in stable angina pectoris. Anatol J Cardiol (2014) 1.97
Reinvestigation of the role of humic acid in the oxidation of phenols by permanganate. Environ Sci Technol (2013) 1.96
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood (2010) 1.86
Structural basis of ultraviolet-B perception by UVR8. Nature (2012) 1.86
Structure of the CRISPR interference complex CSM reveals key similarities with cascade. Mol Cell (2013) 1.74
Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible Hsp molecular chaperones. J Cell Biochem (2002) 1.73
Framework for performance evaluation of face, text, and vehicle detection and tracking in video: data, metrics, and protocol. IEEE Trans Pattern Anal Mach Intell (2009) 1.72
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood (2011) 1.70
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol (2006) 1.69
Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol (2004) 1.68
Enhance the optical absorptivity of nanocrystalline TiO2 film with high molar extinction coefficient ruthenium sensitizers for high performance dye-sensitized solar cells. J Am Chem Soc (2008) 1.68
Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res (2010) 1.67
Conventional US, US elasticity imaging, and acoustic radiation force impulse imaging for prediction of malignancy in thyroid nodules. Radiology (2014) 1.67
Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension (2007) 1.66
c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk Res (2009) 1.64
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem (2013) 1.63
Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol (2009) 1.63
Hypertension alters GABA receptor-mediated inhibition of neurons in the nucleus of the solitary tract. Am J Physiol Regul Integr Comp Physiol (2003) 1.63
Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology (2006) 1.63
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. Microbes Infect (2005) 1.62
Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation. Diabetes (2007) 1.62
Fine mapping and identification of a candidate gene SSH1 in disseminated superficial actinic porokeratosis. Hum Mutat (2004) 1.59
Neuregulin 1 regulates excitability of fast-spiking neurons through Kv1.1 and acts in epilepsy. Nat Neurosci (2011) 1.58
Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One (2009) 1.58
Wound-induced ATP release and EGF receptor activation in epithelial cells. J Cell Sci (2007) 1.54
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Innate immune response of corneal epithelial cells to Staphylococcus aureus infection: role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci (2004) 1.53
Immunization status and risk factors of migrant children in densely populated areas of Beijing, China. Vaccine (2009) 1.53
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain (2011) 1.53
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol (2010) 1.52
Efficient hydrogenation of organic carbonates, carbamates and formates indicates alternative routes to methanol based on CO2 and CO. Nat Chem (2011) 1.51
Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Cytometry A (2007) 1.49
A Selective V1A Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock. Crit Care Med (2016) 1.49
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
Plasticity and remodeling of brain. J Neurol Sci (2007) 1.49
Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev (2015) 1.47
Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS One (2012) 1.47
Retracted Factors behind negative attitudes toward cadaveric organ donation: a comparison between medical and non-medical students in China. Transplantation (2014) 1.47
Biventricular pacemaker optimization guided by comprehensive echocardiography-preliminary observations regarding the effects on systolic and diastolic ventricular function and third heart sound. J Am Soc Echocardiogr (2010) 1.47
Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. J Clin Invest (2012) 1.47
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46
Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol (2014) 1.46
Periodontal health and quality of life in patients with chronic obstructive pulmonary disease. Respir Med (2010) 1.45
Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res (2011) 1.44
Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis (2010) 1.44
Localization of an NH(2)-terminal disease-causing mutation hot spot to the "clamp" region in the three-dimensional structure of the cardiac ryanodine receptor. J Biol Chem (2007) 1.43
UniPep--a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol (2006) 1.43
Retracted Recent advances in DENV receptors. ScientificWorldJournal (2013) 1.43
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res (2011) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
A spectral identity mapper for chemical image analysis. Appl Spectrosc (2004) 1.42
Determinants of high weight gain and high BMI status in the first three months in urban Chinese infants. Am J Hum Biol (2012) 1.42
A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid. Br J Haematol (2014) 1.42
Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol (2005) 1.42
Anomalous origin of a coronary artery from the right branchiocephalic trunk associated with complex congenital heart disease. Pediatr Cardiol (2009) 1.41
Spin-orbit coupled degenerate Fermi gases. Phys Rev Lett (2012) 1.40
Glycogen synthase kinase 3β regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity (2010) 1.39
Cyclosporine Combined with Levamisole for Lower-Risk Myelodysplastic Syndromes. Acta Haematol (2015) 1.38
Novel AroA with high tolerance to glyphosate, encoded by a gene of Pseudomonas putida 4G-1 isolated from an extremely polluted environment in China. Appl Environ Microbiol (2005) 1.38
Temperature can influence gastric accommodation and sensitivity in functional dyspepsia with epigastric pain syndrome. Dig Dis Sci (2012) 1.38
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis (2012) 1.38
Targeted disruption of the heat shock transcription factor (hsf)-2 gene results in increased embryonic lethality, neuronal defects, and reduced spermatogenesis. Genesis (2003) 1.37
Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet (2006) 1.37
Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res (2010) 1.37
Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med (2006) 1.37
A two-stage linkage analysis of Chinese schizophrenia pedigrees in 10 target chromosomes. Biochem Biophys Res Commun (2006) 1.37